Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 1 , ISSUE 1 ( January-June, 2011 ) > List of Articles


HLA Status and Antithyroid Autoantibodies in Egyptian Patients with Chronic Hepatitis C Virus Infection

Yahia Zakaria Gad, Mahmoud El-Bendary, Mona Mahmoud Arafa, Zakaria Fawzy Lotfy

Citation Information : Zakaria Gad Y, El-Bendary M, Mahmoud Arafa M, Fawzy Lotfy Z. HLA Status and Antithyroid Autoantibodies in Egyptian Patients with Chronic Hepatitis C Virus Infection. Euroasian J Hepatogastroenterol 2011; 1 (1):15-18.

DOI: 10.5005/jp-journals-10018-1003

License: CC BY-NC 4.0

Published Online: 01-09-2010

Copyright Statement:  Copyright © 2011; The Author(s).


Background/Aim: The role of hepatitis C virus (HCV) has been demonstrated in many autoimmune diseases, including the autoimmune thyroid disease. However, there is paucity of information about the prevalence of extrahepatic autoimmune phenomenon in HCV-infected patients from Egypt and developing countries. This study checked the prevalence of antithyroid autoantibodies in patients with chronic HCV infection and their possible relation to the human leukocyte antigen (HLA) status. Patients and methods: Sera from 147 consecutive patients (75 males and 72 females) with chronic HCV infection at the Mansoura University Hospitals, Egypt during 2008 to 2009, were analyzed for antithyroid antibodies (group 1). A total of 126 anti-HCV positive patients without antithyroid antibodies were enrolled as controls (group 2). Thyroid microsomal and thyroglobulin autoantibodies were determined by the hemagglutination tests. IgG type anti-GOR were measured using an ELISA assay. HLA-A,-B, -C and -DR were determined using the standard complement-dependent microdroplet lymphocyte cytotoxicity test. Results: Antithyroid antibodies were detected in 21 HCV RNA positive patients (group 1; 18 females, 3 males) and remaining 126 patients (group 2; 72 males and 54 females). The prevalence of anti-GOR antibodies was significantly higher in patients of group 1 compared to that of group 2. A statistically significant difference was observed regarding anti-GOR antibodies in group 1 (p < 0.001), antithyroid autoantibodies among the females (p < 0.001). HLA-A2 antigen was prevalent in group 1 (p < 0.05). Conclusion: Our data revealed that HLA-A2 may be regarded as an immunologic risk factor for the development of antithyroid autoantibodies in patients with chronic HCV infection and these autoantibodies should be evaluated prior to initiating IFN-α therapy.

PDF Share
  1. Torres MR, Bedoya CF, Lasanta GO, Cuetara AM, Rivera JJ. Thyroid dysfunction among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann of Hepatol 2008;7(1): 72-77
  2. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117(1):60-61
  3. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol 1996; 44(6):635-42
  4. Multiple changes in thyroid function in patients with chronic active hepatitis C treated with recombinant interferon-alpha. Am J Med 1996;101(5):482-87
  5. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: A prospective cohort study. Arch Intern Med 2004;164(21): 2371-76
  6. Autoimmune and lymphoproliferative HCV correlated manifestations: Example of mixed cryoglobulinaemia (review). G Ital Nefrol 2004;21(3): 225-37
  7. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontining interferon therapy. Arch Intern Med 1998;158(13):1445-48
  8. Prevalence of HCV antibodies in autoimmune thyroid disease. Eur Rev Med Pharmacol Sci 2006;10(4):183-86
  9. Non-A, non-B hepatic specific antibodies at host derived epitope: Implication of autoimmune process. Lancet 1990;336:1400-03
  10. Microdroplet testing for HLA- A,-B, -C, -D antigens. Am J Clin Pathol 1978;69:103-20
  11. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994;19:841-48
  12. Reversibility of thyroid dysfunction induce by recombinant alpha interferon in chronic hepatitis C. Clin Endocinol 1993;39:657-61
  13. Prevalence of antithyroid peroxidase antibodies in serum in the elderly: Comparison with the other tests for antithyroid antibodies. Clin Chem 1992;38:88-92
  14. Thyroid antibodies in blood donors: Prevalence and clinical significance. Acta Endocrinol 1984;105:324-29
  15. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1992;16:244-45
  16. Evaluation of TPO antibody determination in various clinical situations. In : Carayon P, Ruf J (Eds). Thyroperoxidase and thyroid autoimmunity. Colloque INSERM/ John Libbey Eurotext Ltd 1990;279-315
  17. Lowtitre autoantibodies predict autoimmune disease during interferon alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol 1999;14(5):419-22
  18. Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. J Hepatol 1993;17:253-57
  19. Anti-Gor and hepatitis C virus in autoimmune liver diseases. Lancet 1992;339:267-69
  20. Virus-induced autoimmunity in hepatitis C virus infections: A rare event. J Med Virol 1994;42:66-72
  21. High prevalence of antibodies to hepatitis C virus (HCV) in patients with antithyroid autoantibodies. J Hepatol 1993;18:136-38
  22. The pathogenesis of autoimmune thyroid disease. N Engl J Med 1991;325:278-79
  23. HLA-A and DPB1 loci confer susceptibility to Grave’s disease. Hum Immunol 1992;35:165-72
  24. HLA antigens in patients with interferon-α induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999;30:794- 800.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.